1,3-dimethyl-6-[(E)-2-nitroethenyl]pteridine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 1,3-dimethyl-6-[(E)-2-nitroethenyl]pteridine-2,4-dione
• 化学式: C10H9N5O4
• 分子量: 263.21
• InChiKey: OLOUILMHNUVEDA-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  112
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Immunosuppressive effects of pteridine derivatives
  申请人：——

  公开号：US20030236255A1

  公开（公告）日：2003-12-25

  Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.

  新型多取代的喹啉二酮（卢马嗪），以及单取代或多取代的2-硫代卢马嗪，4-硫代卢马嗪或2,4-二硫代卢马嗪，在喹啉环的1、3、6和7位上具有已披露的取代基，并且其药学上可接受的盐，在制备药物组合物中作为生物活性成分特别用于治疗或预防中枢神经系统疾病、细胞增殖障碍、病毒感染、免疫或自身免疫障碍或移植排斥。本发明的喹啉衍生物与免疫抑制剂或免疫调节剂药物、抗肿瘤药物或抗病毒药物的组合，提供潜在的协同效应。
• IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
  申请人：K.U. Leuven Research & Development

  公开号：EP1187615A2

  公开（公告）日：2002-03-20
• US6946465B2
  申请人：——

  公开号：US6946465B2

  公开（公告）日：2005-09-20
• [EN] IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES<br/>[FR] EFFETS IMMUNOSUPPRESSEURS DES DERIVES DE PTERIDINE
  申请人：LEUVEN K U RES & DEV

  公开号：WO2000045800A2

  公开（公告）日：2000-08-10

  The invention relates to a pharmaceutical composition for the treatment of autoimmuno disorders and/or for the treatment or prevention of transplant-rejections comprising a pteridine derivative of general formula (I) especially a lumazine optionally combined with a second active agent.